Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Research context
Bionomics Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Bionomics Limited is currently in a long term uptrend where the price is trading 1.4% above its 200 day moving average.
From a valuation standpoint, the stock is 1170.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3269.6.
Bionomics Limited's total revenue rose by 1.2% to $102K since the same quarter in the previous year.
Its net income has increased by 99.8% to $-13K since the same quarter in the previous year.
Finally, its free cash flow fell by 853.9% to $-658K since the same quarter in the previous year.
Based on the above factors, Bionomics Limited gets an overall score of 3/5.